Curis Reports Q1 2026 Earnings with Net Loss of $24.2 Million
Curis (CRIS) reported a net loss of $24.2 million for the first quarter of 2026, consistent per share losses compared to the prior year period. The company noted reduced R&D expenses and updated its cash position at $15 million with potential additional funding from PIPE financing.
Topics: clinical_trials pharmaceuticals pipeline_development